litlas
Log inCreate account

Geert D’Haens

Active 1993–2026

Also published as
Geert D'Haens · Geert d’Haens
375
Papers
65,856
Citations
124
h-index
347
i10-index

Citations

Citations per year for Geert D’Haens1990: 2 citations1991: 2 citations1993: 2 citations1994: 1 citations1995: 4 citations1996: 6 citations1997: 5 citations1998: 10 citations1999: 29 citations2000: 44 citations2001: 90 citations2002: 152 citations2003: 133 citations2004: 160 citations2005: 181 citations2006: 178 citations2007: 162 citations2008: 216 citations2009: 291 citations2010: 372 citations2011: 402 citations2012: 405 citations2013: 501 citations2014: 542 citations2015: 567 citations2016: 548 citations2017: 604 citations2018: 668 citations2019: 2,296 citations2020: 2,483 citations2021: 2,171 citations2022: 1,988 citations2023: 2,084 citations2024: 3,113 citations2025: 1,737 citations2026: 37 citations1992: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,782 citing papers, 19% of this breakdownUnited Kingdom: 1,522 citing papers, 7.6% of this breakdownChina: 1,399 citing papers, 7% of this breakdownItaly: 1,336 citing papers, 6.7% of this breakdownCanada: 1,223 citing papers, 6.1% of this breakdownFrance: 1,098 citing papers, 5.5% of this breakdownGermany: 1,005 citing papers, 5.1% of this breakdownNetherlands: 864 citing papers, 4.3% of this breakdownBelgium: 804 citing papers, 4% of this breakdownSpain: 710 citing papers, 3.6% of this breakdownJapan: 571 citing papers, 2.9% of this breakdownAustralia: 534 citing papers, 2.7% of this breakdown
0%19%Other 25.5%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology57.4%
  • Medicine31.7%
  • Immunology and Microbiology6.1%
  • Neuroscience1%
  • Nursing0.9%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • Other2.3%

Topics

  • Inflammatory Bowel Disease20.1%
  • Microscopic Colitis7.4%
  • Gut microbiota and health4.1%
  • Rheumatoid Arthritis Research and Therapies3.5%
  • Autoimmune and Inflammatory Disorders3%
  • Biosimilars and Bioanalytical Methods2.3%
  • Other59.6%

Coauthors

All papers

Open in search
  1. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: William J. Sandborn, Chinyu Su, Bruce E. Sands, Geert D’Haens, Séverine Vermeire, Stefan Schreiber, Silvio Danese, Brian G. Feagan, Walter Reinisch, Wojciech Niezychowski, Gary S. Friedman, Nervin Lawendy, Dahong Yu, Deborah Woodworth, Arnab Mukherjee, Haiying Zhang, Paul J. Healey, Julián Panés - New England Journal of Medicine 2017 cited by 1,727

  2. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

    Authors: Silvio Danese, Séverine Vermeire, Wen Zhou, Aileen L. Pangan, Jesse Siffledeen, Susan Greenbloom, Xavier Hébuterne, Geert D’Haens, Hiroshi Nakase, Julián Panés, Peter Higgins, Pascal Juillerat, James O. Lindsay, Edward V. Loftus, William J. Sandborn, Walter Reinisch, Minhu Chen, Yuri Sánchez González, Bidan Huang, Wangang Xie, John Liu, Michael Weinreich, Remo Panaccione - The Lancet 2022 cited by 597

  3. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

    Authors: Edward V. Loftus, Julián Panés, Ana P. Lacerda, Laurent Peyrin‐Biroulet, Geert D’Haens, Remo Panaccione, Walter Reinisch, Édouard Louis, Minhu Chen, Hiroshi Nakase, Jakob Begun, Brigid S. Boland, Charles D. Phillips, Mohamed‐Eslam F. Mohamed, Jianzhong Liu, Ziqian Geng, Tian Feng, Elena Dubcenco, Jean‐Frédéric Colombel - New England Journal of Medicine 2023 cited by 427

  4. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

    Authors: Marco Daperno, Geert D’Haens, Gert Van Assche, Filip Baert, P. Bulois, V. Maunoury, R. Sostegni, Rodolfo Rocca, A. Pera, Annemie Gevers, Jean-Yves Mary, Jean-Frédéric Colombel, Paul Rutgeerts - Gastrointestinal Endoscopy 2004 cited by 1,774

  5. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

    Authors: William J. Sandborn, Séverine Vermeire, Laurent Peyrin‐Biroulet, Marla C. Dubinsky, Julián Panés, Andrés Yarur, Timothy E. Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Douglas C. Wolf, Bruce E. Sands, Geert D’Haens, Silvio Danese, Martina Goetsch, Brian G. Feagan - The Lancet 2023 cited by 333

  6. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

    Authors: Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch, Gerassimos J. Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, Simon Lichtiger, Geert D’Haens, Robert H. Diamond, Delma L. Broussard, Kezhen L. Tang, C. Janneke van der Woude, Paul Rutgeerts - New England Journal of Medicine 2010 cited by 3,108

  7. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: William J. Sandborn, Brian G. Feagan, Geert D’Haens, Douglas C. Wolf, Igor Jovanović, Stephen B. Hanauer, Subrata Ghosh, AnnKatrin Petersen, Steven Y. Hua, Ji Hwan Lee, Lorna Charles, Denesh K. Chitkara, Keith Usiskin, Jean–Frédéric Colombel, Loren Laine, Silvio Danese - New England Journal of Medicine 2021 cited by 532

  8. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

    Authors: Geert D’Haens, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean–Frédéric Colombel, Silvio Danese, Marla C. Dubinsky, Brian G. Feagan, Tadakazu Hisamatsu, Allen Lim, James O. Lindsay, Edward V. Loftus, Julián Panés, Laurent Peyrin‐Biroulet, Zhihua Ran, David T. Rubin, William J. Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W. Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Marc Ferrante - The Lancet 2022 cited by 387

  9. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

    Authors: Laurent Peyrin‐Biroulet, William J. Sandborn, Bruce E. Sands, Walter Reinisch, Willem A. Bemelman, Robert V. Bryant, Geert D’Haens, Iris Dotan, Marla C. Dubinsky, Brian G. Feagan, Gionata Fiorino, Richard B. Gearry, Suneeta Krishnareddy, Péter L. Lakatos, Edward V. Loftus, Philippe Marteau, Pia Munkholm, Travis B. Murdoch, Íngrid Ordás, Remo Panaccione, Robert H. Riddell, Joannie Ruel, David T. Rubin, Mark Samaan, Corey A. Siegel, Mark S. Silverberg, Jaap Stoker, S Schreiber, Simon Travis, Gert Van Assche, Silvio Danese, Julián Panés, Guillaume Bouguen, Sarah O’Donnell, Benjamin Pariente, Shawn Winer, Stephen B. Hanauer, J -F Colombel - The American Journal of Gastroenterology 2015 cited by 1,838

  10. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: Geert D’Haens, Marla C. Dubinsky, Taku Kobayashi, Peter M. Irving, Stefanie Howaldt, Juris Pokrotnieks, Kathryn A. Krueger, Janelle Laskowski, Xingyuan Li, Trevor Lissoos, Joe Milata, Nathan Morris, Vipin Arora, Catherine Milch, William J. Sandborn, Bruce E. Sands - New England Journal of Medicine 2023 cited by 317

  11. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

    Authors: Jean‐Frédéric Colombel, Remo Panaccione, Peter Bossuyt, Milan Lukáš, Filip Baert, Tomáš Vaňásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hébuterne, Simon Travis, Silvio Danese, Walter Reinisch, William J. Sandborn, Paul Rutgeerts, Daniël W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Paloma Méndez, Joel Petersson, Kori Wallace, Anne Robinson, Roopal Thakkar, Geert D’Haens - The Lancet 2017 cited by 912

  12. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

    Authors: Marc Ferrante, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean–Frédéric Colombel, Silvio Danese, Marla C. Dubinsky, Brian G. Feagan, Tadakazu Hisamatsu, Allen Lim, James O. Lindsay, Edward V. Loftus, Julián Panés, Laurent Peyrin‐Biroulet, Zhihua Ran, David T. Rubin, William J. Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W. Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Geert D’Haens - The Lancet 2022 cited by 316

  13. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

    Authors: Bram Verstockt, Azucena Salas, Bruce E. Sands, Clara Abraham, Haim Leibovitzh, Markus F. Neurath, Niels Vande Casteele, Silvio Danese, Geert D’Haens, Lars Eckmann, William A. Faubion, Brian G. Feagan, Vipul Jairath, Christopher Ma, Saurabh Mehandru, Julián Panés, Florian Rieder, William J. Sandborn, Mark S. Silverberg, Marisol Veny, Séverine Vermeire, Stefania Vetrano - Nature Reviews Gastroenterology & Hepatology 2023 cited by 231

  14. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

    Authors: Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, J. Załuski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, G. Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier - New England Journal of Medicine 2009 cited by 3,868

  15. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis

    Authors: Noortje Rossen, Susana Fuentes, Mirjam J. van der Spek, Jan G.P. Tijssen, Jorn Hartman, Ann Duflou, Mark Löwenberg, Gijs R. van den Brink, Elisabeth M. H. Mathus-Vliegen, Willem M. de Vos, Erwin G. Zoetendal, Geert D’Haens, Cyriel Y. Ponsioen - Gastroenterology 2015 cited by 931

  16. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

    Authors: William J. Sandborn, Brian G. Feagan, Edward V. Loftus, Laurent Peyrin‐Biroulet, Gert Van Assche, Geert D’Haens, Stefan Schreiber, Jean‐Frédéric Colombel, James D. Lewis, Subrata Ghosh, Alessandro Armuzzi, Ellen Scherl, Hans Herfarth, L.M. Vitale, Mohamed‐Eslam F. Mohamed, Ahmed A. Othman, Qian Zhou, Bidan Huang, Roopal Thakkar, Aileen L. Pangan, Ana P. Lacerda, Julián Panés - Gastroenterology 2020 cited by 317

  17. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial

    Authors: Nurulamin M Noor, James Lee, Simon Bond, Francis Dowling, Biljana Brezina, Kamal Patel, Tariq Ahmad, Paul Banim, James Berrill, Rachel Cooney, Juan De La Revilla Negro, Shanika de Silva, Shahida Din, Dharmaraj Durai, J Gordon, Peter M. Irving, Matthew W. Johnson, Alexandra Kent, Klaartje Kok, Gordon W. Moran, Craig Mowat, Pritash Patel, C Probert, Tim Raine, Rebecca Saich, Abigail Seward, Dan Sharpstone, Melissa Smith, Sreedhar Subramanian, Sara Upponi, Alan A. Wiles, Horace R. Williams, Gijs R. van den Brink, Séverine Vermeire, Vipul Jairath, Geert D’Haens, Eoin McKinney, Paul Lyons, James O. Lindsay, Nicholas A. Kennedy, Kenneth G. C. Smith, Miles Parkes, Nurulamin M Noor, James Lee, Simon Bond, Francis Dowling, Biljana Brezina, Kamal Patel, Tariq Ahmad, Paul Banim, James Berrill, Rachel Cooney, Juan De La Revilla Negro, Shanika de Silva, Shahida Din, Dharmaraj Durai, J Gordon, Peter M. Irving, Matthew W. Johnson, Alexandra Kent, Klaartje Kok, Gordon W. Moran, Craig Mowat, Pritash Patel, C Probert, Tim Raine, Rebecca Saich, Abigail Seward, Dan Sharpstone, Melissa Smith, Sreedhar Subramanian, Sara Upponi, Alan A. Wiles, Horace R. Williams, Gijs van Den Brink, Séverine Vermeire, Vipul Jairath, Geert D’Haens, Eoin McKinney, Paul Lyons, James O. Lindsay, Nicholas A. Kennedy, Kenneth G. C. Smith, Miles Parkes, Clare Allcock, Suhaylah Bhatti, Jonathan Blackwell, Robert Boulton-Jones, Matthew Brookes, Rhys O. Butcher, Jeffrey Butterworth, Karlena Champion, Rakesh Chaudhary, Andy Cole, Lauranne Derikx, Anjan Dhar, Mary Flowerdew, Rishi Goel, Ailsa Hart, R Hughes and 17 more - ˜The œLancet. Gastroenterology & hepatology 2024 cited by 281

  18. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

    Authors: William J. Sandborn, Geert D’Haens, Walter Reinisch, Julián Panés, Daphne Chan, Susana Gonzalez, Kathleen Weisel, Matthew Germinaro, Mary Ellen Frustaci, Zijiang Yang, Omoniyi J. Adedokun, Chenglong Han, Remo Panaccione, Tadakazu Hisamatsu, Silvio Danese, David T. Rubin, Bruce E. Sands, Anita Afzali, Jane M. Andrews, Brian G. Feagan - Gastroenterology 2022 cited by 198

  19. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling

    Authors: Pim J. Koelink, Felicia M. Bloemendaal, Bofeng Li, Liset Westera, Esther Vogels, Manon van Roest, Anouk K. Gloudemans, Angélique B. van ’t Wout, Hannelie Korf, Séverine Vermeire, Anje A. te Velde, Cyriel Y. Ponsioen, Geert D’Haens, J. Sjef Verbeek, Terrence L. Geiger, Manon E. Wildenberg, Gijs R. van den Brink - Gut 2019 cited by 225

  20. Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

    Authors: William J. Sandborn, Gert Van Assche, Walter Reinisch, Jean‐Frédéric Colombel, Geert D’Haens, Douglas C. Wolf, Martina Kron, Mary Beth Tighe, Andreas Lazar, Roopal Thakkar - Gastroenterology 2011 cited by 1,258

  21. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

    Authors: William J. Sandborn, Filip Baert, Silvio Danese, Željko Krznarić, Taku Kobayashi, Xiaopan Yao, Jingjing Chen, Maria Rosario, Siddharth Bhatia, Krisztina Kisfalvi, Geert D’Haens, Séverine Vermeire - Gastroenterology 2019 cited by 317

  22. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

    Authors: Séverine Vermeire, Geert D’Haens, Filip Baert, Silvio Danese, Taku Kobayashi, Edward V. Loftus, Siddharth Bhatia, Christian Agboton, Maria Rosario, Chunlin Chen, Wenwen Zhang, Krisztina Kisfalvi, William J. Sandborn - Journal of Crohn s and Colitis 2021 cited by 170

  23. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease

    Authors: Bruce E. Sands, Laurent Peyrin‐Biroulet, Jarosław Kierkuś, Peter Higgins, Monika Fischer, Vipul Jairath, Fumihito Hirai, Geert D’Haens, Ruth M. Belin, Debra L. Miller, Elisa Gomez‐Valderas, April N. Naegeli, Jay Tuttle, Paul F. Pollack, William J. Sandborn - Gastroenterology 2021 cited by 149

  24. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

    Authors: Bruce E. Sands, Brian G. Feagan, Paul Rutgeerts, Jean‐Frédéric Colombel, William J. Sandborn, Richmond Sy, Geert D’Haens, Shomron Ben‐Horin, Jing Xu, Maria Rosario, Irving H. Fox, Asit Parikh, Catherine Milch, Stephen B. Hanauer - Gastroenterology 2014 cited by 705